CTD-ILD Physicians See Significant Unmet Need Despite New Therapies

Industry
โดย Spherix Global Insights·Read original
Summary · why it matters

A new Spherix Global Insights study finds that only 15% of connective tissue disease-associated interstitial lung disease patients achieve drug-free remission, and most physicians remain dissatisfied with current treatments. The survey of 54 rheumatologists and 53 pulmonologists in March 2026 shows heavy reliance on mycophenolate mofetil, corticosteroids, rituximab, tocilizumab, and antifibrotics, while Boehringer Ingelheim's newly approved Jascayd has gained early traction and is viewed favorably over OFEV on tolerability and efficacy. Rheumatologists express strong interest in GSK's Benlysta and Bristol Myers Squibb's investigational CAR-T therapy zola-cel for its potential to reverse fibrosis, while pulmonologists favor United Therapeutics' Tyvaso and oral LPA1 antagonists as next-generation antifibrotics. The findings highlight a rapidly evolving pipeline that physicians hope will move beyond slowing progression to meaningful disease modification.

Impact on stocks 3

Biotech & Genomic Medicine▲ · 3 stocks
Bristol-Myers Squibb Company
BMY
▲ PositiveTechnologyrelevance

Rheumatologists express strong interest in BMS's investigational CAR-T therapy zola-cel for its potential to reverse fibrosis.

GSK plc
GSK
▲ PositiveDemandrelevance

Rheumatologists express strong interest in GSK's Benlysta for CTD-ILD, indicating potential demand.

Theme Impact 2

Off-coverage companies 2

Boehringer Ingelheim International GmbHPrivate▲ Positive
Demandrelevance

Boehringer Ingelheim's newly approved Jascayd has gained early traction and is viewed favorably over OFEV on tolerability and efficacy.

Spherix Global InsightsPrivate± Mixed
relevance

Related news

▲

Bristol Myers Sotyktu Shows Two-Year PsA Efficacy in POETYK Study

Bristol Myers Squibb announced positive two-year results from the late-stage POETYK PsA-2 study of Sotyktu, or deucravacitinib, including its open-label extension. Among patients entering the extension, clinical responses improved from week 16 through week 52 and were sustained through week 104, with robust results across ACR20/50/70 and Minimal Disease Activity in both continuous Sotyktu patients and those who switched from placebo at week 16. The safety profile remained consistent through week 104 with no new safety signals; adverse events occurred in 86.6% of 604 patients exposed to Sotyktu, while serious adverse events and discontinuations due to adverse events were reported in 12.6% and 7.6% of patients, respectively. Sotyktu, an oral selective tyrosine kinase 2 inhibitor approved in the United States and numerous other countries for moderate-to-severe plaque psoriasis and active psoriatic arthritis, generated $156 million in first-half 2026 revenues, up 24% year over year. Data from the POETYK SLE-1 and SLE-2 studies in systemic lupus erythematosus are expected later in 2026, while Amgen's Otezla and Takeda's investigational zasocitinib, whose new drug application the FDA recently accepted for plaque psoriasis, remain competitive threats.
BMY ▲
Biotech & Genomic Medicine ▲
Zacks Investment Research·10hRead more →
3

Novo's Denecimig Wins CHMP Backing for Hemophilia A in EU

Novo Nordisk said the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending approval of denecimig, also known as Mim8, for the treatment of hemophilia A, with or without inhibitors, in adults and children. Denecimig is a next-generation factor VIIIa mimetic bispecific antibody given subcutaneously as routine prophylaxis, with flexible dosing that includes once-monthly, every-two-week and weekly administration, and it is being developed as a prefilled pen. Novo expects to launch the drug in the first European countries in the fourth quarter of 2026 under the brand name Frehemgo, followed by a broader rollout across the European Union beginning in early 2027. The positive opinion is supported by data from the FRONTIER clinical program, which comprises five studies evaluating denecimig as a prophylactic treatment for hemophilia A across pediatric and adult populations, with or without inhibitors; in the FRONTIER 2 study denecimig significantly reduced annualized bleeding rates, results in children younger than 12 in FRONTIER 3 were consistent with those in adolescents and adults, and in FRONTIER 5 no new safety concerns were identified when participants switched directly from emicizumab to denecimig. The candidate is also under regulatory review in the United States for routine prophylaxis in adults and children with hemophilia A, with or without inhibitors, after Novo submitted a biologics license application to the FDA in September 2025. Novo already markets Alhemo for hemophilia A and B in patients with or without inhibitors.
ACIUALDXNOV.XETRAPGEN
Biotech & Genomic Medicine ▲
Zacks Investment Research·14hRead more →
▼impact 4

Trump to Announce Most Favored Nation Drug Pricing for Medicaid in All 50 States

President Trump will announce on Friday that Medicaid beneficiaries in all 50 states will receive Most Favored Nation pricing discounts on some prescription drugs. The White House Council of Economic Advisers projects the move will generate $27.6B in savings for state governments and $36.6B for the federal government over 10 years, according to Semafor, which broke the news. Trump is also scheduled to meet today with the governors of Arkansas, Mississippi, and South Dakota to discuss progress on lowering drug prices. Separately, an AARP Public Policy Institute report released in August found that applying MFN pricing to the top 10 drugs by Medicare Part D and Part B spending in 2025 would cut Medicare spending on those drugs from $273B to $76B between 2029 and 2033.
ABBVJNJLLYMRKNOV.XETRAPFE+1
Biotech & Genomic Medicine ▼
Seeking Alpha·15hRead more →
© 2026 MarketDXNews